Home » Newsletters » BioWorld Science

BioWorld Science

May 6, 2019

View Archived Issues

Molecular subtyping identifies problematic lung nodules

Fusion protein hVEGF121-M2-GnRH3-hinge-MVP is immunogenic and inhibits prostate tumor growth in mice

AN-12855: improved efficacy and resistance potential vs. isoniazid in M. tuberculosis mouse model

Mayo Clinic initiates phase I study of AR-160 in relapsed or refractory B-cell NHL

Phase I study of Sc-rAAV2.5IL-1Ra in moderate knee OA now enrolling participants

Data from phase IIb study of inhaled alprazolam for acute seizure rescue treatment reported at AAN

Creston presents CRS-0540 for treating infections with resistant Gram-positive pathogens

NIAID initiates phase I study of a trispecific broadly neutralizing antibody against HIV

Cialis returns to Viagra's roots

ALY-688 shows efficacy in atropine-induced rabbit model of dry eye disease

KR-67607 shows potential as neuroprotective therapeutic agent for glaucoma

TOP-1257, a potent inhibitor of inflammation and angiogenesis

Prion may be answer to Alzheimer's amyloid riddle

Preclinical data support development of AB-2004 for GI dysfunction in autism spectrum disorder

First-in-human data presented for PBT-434 alpha-synuclein aggregation inhibitor

Syros Pharmaceuticals identifies new tyrosine-protein kinase inhibitors

Genentech and Roche present RIPK1 inhibitors

Ramot at Tel Aviv University discloses compounds for neuropathic pain

AbbVie initiates phase III study of ABBV-951 in Parkinson's disease

FDA approves Kadcyla for adjuvant treatment in HER2-positive early breast cancer setting

Shanxi Medical University patents EMSCs for cardiovascular diseases

Preliminary data from OLE study of Liproca depot suggest longer treatment intervals

SK Bioscience synthesizes compounds for RSV infections

Preliminary data from phase I study of Oraxol in angiosarcoma show complete responses

High rates of remission seen with KTE-X19 in young patients with B-cell acute lymphoblastic leukemia

Novel potent mGlu7 negative allosteric modulator with high CNS penetration and favorable properties

Kazia reports safety data from phase IIa study of GDC-0084 in newly diagnosed glioblastoma

Connect Biopharma reports phase I data and new study in atopic dermatitis with CBP-201

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...